Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 166

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer

Open access
Bader, David A., Hartig, Sean M., Putluri, Vasanta, Foley, Christopher, Hamilton, Mark P., Smith, Eric A., Saha, Pradip K., Panigrahi, Anil, Walker, Christopher, Zong, Lin, Martini-Stoica, Heidi, Chen, Rui, Rajapakshe, Kimal, Coarfa, Cristian, Sreekumar, Arun, Mitsiades, Nicholas, Bankson, James A., Ittmann, Michael M., O’Malley, Bert W., Putluri, Nagireddy, McGuire, Sean E. · 2018 · Nature Metabolism

Abstract

Specific metabolic underpinnings of androgen receptor (AR)-driven growth in prostate adenocarcinoma (PCa) are largely undefined, hindering the development of strategies to leverage the metabolic dependencies of this disease when hormonal manipulations fail. Here we show that the mitochondrial pyruvate carrier (MPC), a critical metabolic conduit linking cytosolic and mitochondrial metabolism, is transcriptionally regulated by AR. Experimental MPC inhibition restricts proliferation and metabolic outputs of the citric acid cycle (TCA) including lipogenesis and oxidative phosphorylation in AR-driven PCa models. Mechanistically, metabolic disruption resulting from MPC inhibition activates the eIF2α/ATF4 integrated stress response (ISR). ISR signalling prevents cell cycle progression while coordinating salvage efforts, chiefly enhancing glutamine assimilation into the TCA, to regain metabolic homeostasis. We confirm that MPC function is operant in PCa tumours in vivo using isotopomeric metabolic flux analysis. In turn, we apply a clinically viable small molecule targeting the MPC, MSDC0160, to pre-clinical PCa models and find that MPC inhibition suppresses tumour growth in hormone-responsive and castrate-resistant conditions. Collectively, our findings characterize the MPC as a tractable therapeutic target in AR-driven prostate tumours. The metabolic dependencies of androgen receptor (AR)-driven growth in prostate adenocarcinoma are largely unknown but could represent a therapeutic target when hormonal manipulations fail. Here the authors demonstrate that the mitochondrial pyruvate carrier (MPC) is transcriptionally regulated by AR and that MPC inhibition suppresses tumour growth in hormone-responsive and castrate-resistant conditions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s42255-018-0002-y

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 166

Metadata

Authors
Bader, D. A., Hartig, S. M., Putluri, V., Foley, C., Hamilton, M. P., Smith, E. A., Saha, P. K., Panigrahi, A., Walker, C., Zong, L., Martini-Stoica, H., Chen, R., Rajapakshe, K., Coarfa, C., Sreekumar, A., Mitsiades, N., Bankson, J. A., Ittmann, M. M., O’Malley, B. W., Putluri, N., & McGuire, S. E.
Venue
Nature Metabolism
Published
2018-11-19
Volume
1
Issue
1
Pages
70-85
ISSN
2522-5812 (ISSN-L)
OpenAlex
W2900888169
Cited by
166
References
15
FWCI
8.96
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer. https://app.cochat.ai/papers/10.1038/s42255-018-0002-y
The paper
Bader, D. A., Hartig, S. M., Putluri, V., Foley, C., Hamilton, M. P., Smith, E. A., Saha, P. K., Panigrahi, A., Walker, C., Zong, L., Martini-Stoica, H., Chen, R., Rajapakshe, K., Coarfa, C., Sreekumar, A., Mitsiades, N., Bankson, J. A., Ittmann, M. M., O’Malley, B. W., . . . McGuire, S. E. (2018). Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer. Nature Metabolism. https://doi.org/10.1038/s42255-018-0002-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.